Rockville, Md.-based CRO  Accelovance has announced the acquisition of Radiant Development, the CRO division of Radiant Research. Terms of the transaction were not disclosed. 

Accelovance, a patient-centric CRO, has seen much of its growth in the vaccine, infectious disease and oncology markets. The addition of Radiant Development broadens Accelovance's ability across a range of therapeutic areas. Radiant Development has performed studies in areas including cardiovascular, men's and women's health, rheumatology, dermatology, oncology and medical device, and also has specialized expertise in consumer health and nutrition.

"We are thrilled to have 100% of the Radiant team led by Vita Lanoce as part of our company," said Stephen J. Trevisan, Accelovance president and CEO.

Operating out of locations in Stuart, Florida; Chicago; and Durham, N.C., Radiant Development is a full-service CRO that has managed over 200 research studies since its inception, and has established strategic partnerships in Europe and Asia.

Radiant Development will operate as a division of Accelovance, providing project management and clinical monitoring, medical, safety and pharmacovigilance, regulatory consulting, medical writing, data management and statistical services.

Current customers, employees and stakeholders of Radiant Development will receive its ongoing, preferred provider relationship with the Radiant Research and Clinical Research Advantage site network.     

Accelovance offers full CRO, clinical sites, patient recruitment and call center services, and has a 100% owned subsidiary providing CRO services in China.  It also has six wholly-owned, research-dedicated clinical sites.